EISAI CLARITYAD BAN2401-G000-301 (Phase 3)

Drug Development Trials

About the trial

A phase 3 open-label extension to confirm the safety and efficacy of lecanemab in subjects with early Alzheimer’s disease. The study medication aims to remove insoluble amyloid plaques and potentially reduce the toxic amyloid that is known to contribute to neuronal degradation in AD.

It is administered via intravenous infusion once a fortnight.